This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Psoriasis
  • /
  • Interleukin-17 antagonists in the treatment of pso...

Interleukin-17 antagonists in the treatment of psoriasis

Read time: 1 mins
Published:4th Mar 2015
Author: Chandrakumar SF, Yeung J.
Availability: Free full text
Ref.: J Cutan Med Surg. 2015 Mar-Apr;19(2):109-14.
Interleukin-17 antagonists in the treatment of psoriasis.

Psoriasis is a chronic, immune-mediated inflammatory skin disorder of unknown etiology. Interleukin (IL)-17a, a key product of the recently identified Th17 cell subset, has been found to play a critical role in the immunopathogenesis of psoriasis. IL-17 antagonists are a new class of biological agent currently in development for psoriasis that selectively inhibit IL-17a activity.

Objective: This review aims to summarize the current efficacy data from phase II randomized controlled trials of the IL-17 antagonists brodalumab, ixekizumab, and secukinumab for the treatment of moderate to severe psoriasis.

Conclusion: Patients treated with IL-17 antagonists achieved marked reduction in psoriasis disease severity as demonstrated by the Psoriasis Area and Severity Index (PASI) 75 response rates. A sizable proportion of patients treated with brodalumab and ixekizumab achieved unprecedented clinical clearance of their psoriasis (PASI > 90). These encouraging results demonstrate the efficacy of these agents and validate the pro-inflammatory role of IL-17 in the pathophysiology of psoriasis.

Read abstract on library site    Access full article